Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 in relapsed or refractory classical Hodgkin lymphoma (China, phase I/II)
CTR20181311Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by Akeso, Inc.. Started Aug 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on CTR20181311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181311.